AngioTarget         Angiostatic strategies for cancer therapy                  





The Company


























Wentink MQ, Hackeng TM, Tabruyn SP, Puijk WC, Schwamborn K, Altschuh D, Meloen RH, Schuurman T, Griffioen AW, Timmerman P Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. Proc.Natl.Acad.Sci USA, In press, 2016

Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW. Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updat. 25:26-37, 2016.

Wentink MQ, Huijbers EJM, De Gruijl TD, Verheul HMW, Olsson AK, Griffioen AW. Vaccination approach to angiostatic treatment of cancer. BBA Cancer 1855:155-71, 2015.

Van Beijnum JR, Dings RPM, Zwaans B, Van der Linden E, Ramaekers FCS, Mayo KH and Griffioen AW. Gene expression of tumor angiogenesis dissected; specific targeting of colon cancer angiogenic vasculature. Blood, 108:2339-2348, 2006.

Dirkx AEM, oude-Egbrink MG, Castermans K, Thijssen VLJL, Van der Schaft DWJ, Dings RPM, Kwee L, Mayo KH, Wagstaff J, Bouma-Ter Steege JCA, Griffioen AW. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20:621-30, 2006.


Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol.Rev. 52: 237-268, 2000






© AngioVacs BV